NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion ... the expression of cellular markers indicating a transition to a powerful cancer-cell killing phenotype.

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

This new platform aims to expand Gamma-Delta T-cells effectively ... INB-619 targets CD19, a marker found on B cells involved in leukemias, lymphomas, and autoimmune conditions.

This groundbreaking platform leverages gamma-delta T cells' unique properties ... targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and ...

The platform's first candidate, INB-619, targets CD19, a key marker broadly found on B cells ... IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta (γδ) T cell-based ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T ... marker broadly found on B cells ...

The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on ... biopharmaceutical company developing gamma-delta (γδ) T cell-based immunotherapies for cancer patients.